Page last updated: 2024-12-07

ginkgolide a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Ginkgolide A is a terpene trilactone compound found in the leaves of the Ginkgo biloba tree. It has been shown to have various pharmacological effects, including anti-inflammatory, anti-oxidant, and neuroprotective properties. Ginkgolide A is a potent inhibitor of platelet-activating factor (PAF), a phospholipid mediator involved in various inflammatory and allergic reactions. This inhibitory effect contributes to its anti-inflammatory properties. Research suggests that Ginkgolide A may also have neuroprotective effects by protecting neurons from damage caused by oxidative stress and excitotoxicity. This makes it a potential therapeutic agent for conditions like Alzheimer's disease. Despite its potential benefits, the synthesis of Ginkgolide A remains challenging due to its complex structure. Researchers are continually exploring ways to synthesize it efficiently for further study and potential clinical applications. The study of Ginkgolide A is driven by its unique biological activities and its potential as a lead compound for the development of new therapeutic drugs.'

Cross-References

ID SourceID
PubMed CID115221
CHEMBL ID1408113
CHEBI ID181554
SCHEMBL ID14029426
MeSH IDM0133138

Synonyms (22)

Synonym
LS-14792
c20h24o9
CHEBI:181554
8-tert-butyl-6,17-dihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
9h-1,7a-(epoxymethano)-1h,6ah-cyclopenta[c]furo[2,3-b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4h)-trione, 3-tert-butylhexahydro-4,7b-dihydroxy-8-methyl-
nsc603665
nsc-603665
15291-75-5
ginkgolide a
NCGC00142512-01
9h-1,7a-(epoxymethano)-1h,6ah-cyclopenta(c)furo(2,3-b)furo(3',2':3,4)cyclopenta(1,2-d)furan-5,9,12(4h)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b-dihydroxy-8-methyl-, (1r,3s,3as,4r,6ar,7ar,7br,8s,10as,11as)-
L000778
NCGC00017329-02
ginkgolide a from ginkgo biloba leaves
9h-1,7a-(epoxymethano)-1h,6ah-cyclopenta[c]furo[2,3-b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4h)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b-dihydroxy-8-methyl-, [1r-(1.alpha.,3.beta.,3as*,4.beta.,6a.alpha.,7a.alpha.,7b.alpha.,8.alpha.,10a.alpha.,11
9h-1,7a-(epoxymethano)-1h,6ah-cyclopenta[c]furo[2,3-b]furo[3',2':3,4]cyclopenta[1,2-d]furan-5,9,12(4h)-trione, 3-(1,1-dimethylethyl)hexahydro-4,7b-dihydroxy-8-methyl-
FPUXKXIZEIDQKW-UHFFFAOYSA-N
ginkgolidea
SCHEMBL14029426
CHEMBL1408113
AKOS024463027
(1s,3r,6r,7s,8s,10r,11s,13s,16s,17r)-8-tert-butyl-6,17-dihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione

Research Excerpts

Overview

Ginkgolide A is a highly active platelet activating factor antagonist cage molecule. It was isolated from the leaves of the Ginkgo biloba L.

ExcerptReferenceRelevance
"Ginkgolide A is a highly active platelet activating factor antagonist cage molecule which was isolated from the leaves of the Ginkgo biloba L. "( Therapeutic promises of ginkgolide A: A literature-based review.
Abdulwanis Mohamed, Z; Faizal Abdull Razis, A; Hossain, R; Islam, MT; Jamaddar, S; Martorell, M; Mondal, M; Pastene-Navarrete, E; Quispe, C; Ray, P; Salehi, B; Sani Jaafaru, M; Sarkar, C; Sharifi-Rad, J, 2020
)
2.31
"Ginkgolide A (GA) is a natural compound isolated from "( Ginkgolide A Ameliorates LPS-Induced Inflammatory Responses In Vitro and In Vivo.
Bao, Y; Hao, F; Huang, Y; Li, Y; Song, Z; Sun, L; Sun, Y; Wang, G; Wu, Y; Yao, X; Yu, C; Zheng, L, 2017
)
3.34
"Ginkgolide A (GA) is a one of the active components of Ginkgo biloba. "( Ginkgolide A inhibits lipopolysaccharide-induced inflammatory response in human coronary artery endothelial cells via downregulation of TLR4-NF-κB signaling through PI3K/Akt pathway.
Feng, L; Jinfeng, L; Kai, W; Luchang, Y; Yequan, S; Zhaocheng, J, 2016
)
3.32

Pharmacokinetics

ExcerptReferenceRelevance
" The method has been successfully applied to a pharmacokinetic study of Ginkgo biloba extract in rats after intravenous administration."( Simultaneous determination of ginkgolides A, B, C and bilobalide in plasma by LC-MS/MS and its application to the pharmacokinetic study of Ginkgo biloba extract in rats.
Ding, C; Ge, Q; Xie, J; Zhi, X; Zhou, Z, 2008
)
0.35
"05), but the Cmax values of BB, GA, GB and GC were significantly decreased (p<0."( Effects of food and gender on the pharmacokinetics of ginkgolides A, B, C and bilobalide in rats after oral dosing with ginkgo terpene lactones extract.
Cai, BC; Chai, C; Di, LQ; Huang, P; Li, JS; Li, W; Qian, XC; Zhang, L, 2014
)
0.4
" For the first time, we showed that the fed dogs had significantly increased area under the concentration-time curve and peak concentration relative to the fasted dogs based on the data from both the prototype form and total lactones of ginkgolide A (GA) and ginkgolide B (GB)."( The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs.
Aa, J; Aa, L; Fei, F; Liu, C; Tan, Z; Wang, G, 2018
)
0.95

Bioavailability

MST may be effective in enhancing the bioavailability of ginkgolide A in GBE.

ExcerptReferenceRelevance
"To study the pharmacokinetics and bioavailability of ginkgolides sustained-release tablet and conventional tablet in Beagle dogs."( [Pharmacokinetics of ginkgolides sustained-release tablet].
Guo, Q; Jin, M; Lv, Y; Sun, X; Xiao, W; Zhang, X, 2011
)
0.37
" The relative bioavailability of ginkgolides A was 88."( [Pharmacokinetics of ginkgolides sustained-release tablet].
Guo, Q; Jin, M; Lv, Y; Sun, X; Xiao, W; Zhang, X, 2011
)
0.37
" To investigate the effects of food and gender on the bioavailability of BB, GA, GB and GC after oral administration of GTL extract, a rapid UPLC-MS/MS method was developed and validated."( Effects of food and gender on the pharmacokinetics of ginkgolides A, B, C and bilobalide in rats after oral dosing with ginkgo terpene lactones extract.
Cai, BC; Chai, C; Di, LQ; Huang, P; Li, JS; Li, W; Qian, XC; Zhang, L, 2014
)
0.4
"To investigate the pharmacokinetic characteristics and absolute bioavailability of ginkgolide A (GA), ginkgolide B (GB) and bilobalide (BB) in rats."( [Absolute bioavailability of ginkgolide compounds in rats].
Geng, T; Si, HH; Sun, XP; Xue, J; Zhao, J, 2015
)
0.64
" To address the poor bioavailability of ginkgo diterpene lactones, ginkgo diterpene lactone meglumine injection (GDLI) was formulated and is commercially available."( Pharmacokinetics and tissue distribution of ginkgolide A, ginkgolide B, and ginkgolide K after intravenous infusion of ginkgo diterpene lactones in a rat model.
Aa, J; Fei, F; Geng, J; Geng, T; Huang, W; Li, Y; Ouyang, B; Peng, Y; Wang, G; Wang, J; Wang, P; Wang, S; Wang, Z; Xiao, W, 2016
)
0.7
" However, few studies have evaluated the bioavailability of ginkgolides and the effects of food on it after oral administration of ginkgolides."( The pharmacokinetics study of ginkgolide A, B and the effect of food on bioavailability after oral administration of ginkgolide extracts in beagle dogs.
Aa, J; Aa, L; Fei, F; Liu, C; Tan, Z; Wang, G, 2018
)
0.77
" These results suggest that MST may be effective in enhancing the bioavailability of ginkgolide A in GBE."( Mixing Ginkgo biloba Extract with Sesame Extract and Turmeric Oil Increases Bioavailability of Ginkgolide A in Mice Brain.
Ayaki, I; Iwamoto, K; Kawamoto, H; Matsumura, S; Moriyama, T; Takeshita, F; Zaima, N, 2019
)
0.96
" GA had a cardioprotective effect in mice with pressure overload, which was closely related with reducing oxidative stress and enhancing NO bioavailability in hearts."( Ginkgolide A protects adverse cardiac remodeling through enhancing antioxidation and nitric oxide utilization in mice with pressure overload.
Wu, X; Wu, Z; Ye, F; You, W, 2019
)
1.96
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
diterpene lactone
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (73)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's1 (1.37)18.2507
2000's28 (38.36)29.6817
2010's32 (43.84)24.3611
2020's12 (16.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 30.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index30.29 (24.57)
Research Supply Index4.37 (2.92)
Research Growth Index6.31 (4.65)
Search Engine Demand Index36.71 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (30.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (2.63%)5.53%
Reviews1 (1.32%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other73 (96.05%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]